全文获取类型
收费全文 | 8964篇 |
免费 | 623篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 67篇 |
儿科学 | 362篇 |
妇产科学 | 237篇 |
基础医学 | 1408篇 |
口腔科学 | 130篇 |
临床医学 | 1295篇 |
内科学 | 1607篇 |
皮肤病学 | 164篇 |
神经病学 | 972篇 |
特种医学 | 207篇 |
外科学 | 721篇 |
综合类 | 79篇 |
一般理论 | 9篇 |
预防医学 | 877篇 |
眼科学 | 150篇 |
药学 | 536篇 |
中国医学 | 9篇 |
肿瘤学 | 787篇 |
出版年
2023年 | 71篇 |
2022年 | 58篇 |
2021年 | 202篇 |
2020年 | 151篇 |
2019年 | 219篇 |
2018年 | 265篇 |
2017年 | 187篇 |
2016年 | 231篇 |
2015年 | 235篇 |
2014年 | 317篇 |
2013年 | 469篇 |
2012年 | 681篇 |
2011年 | 666篇 |
2010年 | 363篇 |
2009年 | 322篇 |
2008年 | 646篇 |
2007年 | 616篇 |
2006年 | 579篇 |
2005年 | 610篇 |
2004年 | 524篇 |
2003年 | 469篇 |
2002年 | 450篇 |
2001年 | 87篇 |
2000年 | 57篇 |
1999年 | 79篇 |
1998年 | 101篇 |
1997年 | 82篇 |
1996年 | 67篇 |
1995年 | 72篇 |
1994年 | 52篇 |
1993年 | 52篇 |
1992年 | 27篇 |
1991年 | 40篇 |
1990年 | 34篇 |
1989年 | 34篇 |
1988年 | 25篇 |
1987年 | 19篇 |
1986年 | 34篇 |
1985年 | 34篇 |
1984年 | 32篇 |
1983年 | 27篇 |
1982年 | 23篇 |
1981年 | 38篇 |
1980年 | 25篇 |
1979年 | 15篇 |
1978年 | 20篇 |
1977年 | 13篇 |
1976年 | 19篇 |
1971年 | 12篇 |
1968年 | 12篇 |
排序方式: 共有9617条查询结果,搜索用时 15 毫秒
91.
92.
93.
Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. 总被引:1,自引:0,他引:1
94.
Cretin S Keeler EB Lynn J Batalden PB Berwick DM Bisognano M 《JAMA》2000,284(14):1786; author reply 1787-1786; author reply 1788
95.
96.
97.
Peter Nieboer Ciska Buijs Sjoerd Rodenhuis Caroline Seynaeve Louk V A M Beex Elsken van der Wall Dick J Richel Marianne A Nooij Emile E Voest Pierre Hupperets Nanno H Mulder Winette T A van der Graaf Els M TenVergert Harm van Tinteren Elisabeth G E de Vries 《Journal of clinical oncology》2005,23(33):8296-8304
PURPOSE: Determine whether standard or high-dose chemotherapy leads to changes in fatigue, hemoglobin (Hb), mental health, muscle and joint pain, and menopausal status from pre- to post-treatment and to evaluate whether fatigue is associated with these factors in disease-free breast cancer patients. PATIENTS AND METHODS: Eight hundred eighty-five patients were randomly assigned between two chemotherapy regimens both followed by radiotherapy and tamoxifen. Fatigue was assessed using vitality scale (score < or = 46 defined as fatigue), poor mental health using mental health scale (score < or = 56 defined as poor mental health) both of Short-Form 36, muscle and joint pain with Rotterdam Symptom Checklist, and Hb levels were assessed before and 1, 2, and 3 years after chemotherapy. RESULTS: Fatigue was reported in 20% of 430 assessable patients (202 standard-dose, 228 high-dose) with at least a 3-year follow-up, without change over time or difference between treatment arms. Mean Hb levels were lower following high-dose chemotherapy. Only 5% of patients experienced fatigue and anemia. Mental health score was the strongest fatigue predictor at all assessment moments. Menopausal status had no effect on fatigue. Linear mixed effect models showed that the higher the Hb level (P = .0006) and mental health score (P < .0001), the less fatigue was experienced. Joint (P < .0001) and muscle pain (P = .0283) were associated with more fatigue. CONCLUSION: In 3 years after treatment, no significant differences in fatigue were found between standard and high-dose chemotherapy. Fatigue did not change over time. The strongest fatigue predictor was poor mental health. 相似文献
98.
Véronique Lenoir Marianne Beau Yon de Jonage-Canonico Marie-Hélène Perrin Antoine Martin Robert Scholler Bernard Kerdelhué 《Breast cancer research : BCR》2005,7(4):R470
Introduction
It has been well documented that the pineal hormone, melatonin, which plays a major role in the control of reproduction in mammals, also plays a role in the incidence and growth of breast and mammary cancer. The curative effect of melatonin on the growth of dimethylbenz [a]anthracene-induced (DMBA-induced) mammary adenocarcinoma (ADK) has been previously well documented in the female Sprague-Dawley rat. However, the preventive effect of melatonin in limiting the frequency of cancer initiation has not been well documented. 相似文献99.
100.
Recent evidence suggest that antagonism of adenosine A2A receptors represent an alternative therapeutic approach to Parkinson's disease (PD). Coactivation of A2A and the glutamate subtype 5 metabotropic receptors (mGlu5) synergistically stimulates DARPP-32 phosphorylation and c-fos expression in the striatum. This study therefore tested the effects of a joint blockade of these receptors to alleviate the motor dysfunction in a rat model of PD. 6-Hydroxydopamine infusions in the striatum produced akinetic deficits in rats trained to release a lever after a stimulus in a reaction time (RT) task. At 2 weeks after the lesion, A2A and mGlu5 receptors selective antagonists 8-(3-chlorostyryl)caffeine (CSC) and 2-methyl-6-(phenylethynyl)-pyridine (MPEP) were administered daily for 3 weeks either as a single or joint treatment. Injections of CSC (1.25 mg/kg) and MPEP (1.5 mg/kg) separately or in combination reduced the increase of delayed responses and RTs induced by 6-OHDA lesions, while the same treatment had no effect in controls. Furthermore, coadministration of lower doses of 0.625 mg/kg CSC and 0.375 mg/kg MPEP noneffective as a single treatment promoted a full and immediate recovery of akinesia, which was found to be more efficient than the separate blockade of these receptors. These results demonstrate that the combined inactivation of A2A and mGlu5 receptor potentiate their beneficial effects supporting this pharmacological strategy as a promising anti-Parkinsonian therapy. 相似文献